Abstract 326P
Background
Indocyanine green (ICG) has the potential to improve sentinel lymph node (SLN) mapping. This current cohort study was designed to assess the value of ICG using a new ICG handheld system with radioisotope (RI) in patients with early breast cancer undergoing SLN biopsy.
Methods
A prospective self-controlled trial compared the detection efficacies of ICG and RI was conducted. Concordance (ICG and RI-positive cases divided by RI-positive cases) and reverse concordance (ICG and RI-positive cases divided by ICG-positive cases) were documented and adverse event were also assessed.
Results
Of 69 patients (median age 56.7 (range 33-85), median BMI 22.6 (range 17.0 – 44.5)) enrolled between 2019 and 2021, 71 SLN biopsies were performed. Sixty-one (85.9%) underwent upfront surgery, while ten (14.1%) were given neoadjuvant treatment. Thirty-four breast-conserving surgeries (BCS) (47.9%), 33 mastectomies (46.5%) and four cryotherapies (5.6%) were performed. No adverse event nor skin staining were reported. The SLN identification rate was 87.3% (62/71) for ICG and 95.8% (68/71) for RI (p=0.13). Dual tracer method resulted in 97.2% successful identification, significantly superior to ICG alone (p=0.04, OR 5.0, CI 1.0-24.1) and and was in line with the reported rate of 96.7% (94.3-99.1)1 by blue dye and RI. Concordance and reverse concordance rates were 89.7% and 98.4%, respectively. A median of 2 lymph nodes was detected by both ICG (range 0 – 6) and IR (range 0 – 5) with no statistical difference (p=0.60). Of 10 cases with 13 metastatic nodes confirmed by histology, both ICG and RI achieved 100% concordance rates. Breast conserving treatments had a higher ICG failure rate compared to mastectomy (21.1% vs 3.0%, p=0.05, OR 8.5, CI 1.0-72.4). In addition, among three cases with prior surgery, two failed ICG SLN identification. Meanwhile, age, BMI, tumour location, multifocality, neoadjuvant treatment, and ICG volume showed no significant correlation with ICG detection rate.
Conclusions
The combined use of ICG and RI ensures adequate SLN identification without problems known with the use of blue dye, such as skin staining and anaphylaxis. A higher failure rate was noted in patients with breast-conserving treatments for ICG tracing.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
313P - Intrinsic subtypes in a cohort of early breast cancer patients
Presenter: Theresa Bracht
Session: Poster session 02
314P - Concordance of somatic variants between circulating tumor DNA and tissue in patients with breast cancer
Presenter: Kangsu Shin
Session: Poster session 02
315P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on perceptions on testing
Presenter: Sarah Powell
Session: Poster session 02
316P - Comprehensive characterization of the HER2-enriched intrinsic molecular subtype in ER-positive HER2-negative breast cancer
Presenter: Lennart Hohmann
Session: Poster session 02
317P - Awareness of genomic testing among patients with breast cancer in Europe
Presenter: Antonella Cardone
Session: Poster session 02
318P - Evaluation of novel diagnostic kits using the semi-dry dot-blot method combined for detecting metastases in sentinel lymph nodes of patients with breast cancer: A multi-center prospective study
Presenter: Ryota Otsubo
Session: Poster session 02
319P - The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer
Presenter: Yumiko Koi
Session: Poster session 02
320P - Clinical and pathological characteristics of breast cancers switching from early luminal-like to metastatic triple-negative phenotype
Presenter: Mariia Ivanova
Session: Poster session 02
321P - Non-BRCA variants in hereditary breast and ovarian cancer patients in the northern Mexico population
Presenter: Dione Aguilar
Session: Poster session 02
322P - Clinicopathological characteristics and genomic profiling of pure mucinous breast cancer
Presenter: Shusen Wang
Session: Poster session 02